- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Omalizumab – November 2016
Omalizumab: Injection 150 mg in 1 mL; Xolair®
Last updated
3 March 2017